← back to search

Anthony P. West

California Institute of Technology · US
Area of research
Virology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include HIV Research and Treatment, Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction, and SARS-CoV-2 and COVID-19 Research.
h-index
69
citations
31,710
works
202
NIH funding
primary concept
Chemistry
email

Recent publications

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope
Nature Immunology 2026cited by 4position: middledoi
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
Nature Immunology 2025cited by 4position: middledoi
Design and characterization of HIV-1 vaccine candidates to elicit antibodies targeting multiple epitopes
The Journal of Experimental Medicine 2025cited by 3position: middledoi
Author Correction: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Nature 2024cited by 4position: middledoi
Germline-encoded amino acid–binding motifs drive immunodominant public antibody responses
Science 2023cited by 89position: middledoi
CD4 binding site immunogens elicit heterologous anti–HIV-1 neutralizing antibodies in transgenic and wild-type animals
Science Immunology 2023cited by 34position: middledoi
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
Science 2022cited by 276position: middledoi
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
Science Advances 2022cited by 24position: middledoi
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Cell Reports 2021cited by 127position: middledoi
Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York
Nature Communications 2021cited by 99position: firstdoi
B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
Cell 2021cited by 99position: middledoi
Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env
Science Translational Medicine 2021cited by 62position: middledoi
Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease
The Journal of Experimental Medicine 2021cited by 55position: middledoi
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
Nature 2020cited by 2,137position: middledoi
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Nature 2020cited by 1,860position: middledoi
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Cell 2020cited by 923position: middledoi
Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate
eLife 2020cited by 69position: middledoi
A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch
eLife 2020cited by 19position: middledoi
Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques
Nature 2019cited by 199position: middledoi
Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
Immunity 2019cited by 100position: middledoi
Combination therapy with anti-HIV-1 antibodies maintains viral suppression
Nature 2018cited by 544position: middledoi
Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope
Nature Communications 2018cited by 119position: middledoi
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Nature Medicine 2017cited by 507position: middledoi
Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico
Cell 2017cited by 352position: middledoi
Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
Science Translational Medicine 2017cited by 176position: middledoi
HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption
Nature 2016cited by 478position: middledoi
HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Science 2016cited by 314position: middledoi
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site
Nature Structural & Molecular Biology 2016cited by 224position: middledoi
Structural basis for germline antibody recognition of HIV-1 immunogens
eLife 2016cited by 77position: middledoi
Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
Nature 2015cited by 768position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Pamela J. Björkman · California Institute of Technology29 papers (2012–2025)Michel C. Nussenzweig · Rockefeller University24 papers (2012–2025)Michael S. Seaman · Harvard University11 papers (2013–2022)Florian Klein · Chirurgische Universitätsklinik Heidelberg9 papers (2013–2022)Christopher O. Barnes · Stanford Medicine9 papers (2018–2024)Harry B. Gristick · California Institute of Technology8 papers (2016–2025)Yu E. Lee · California Institute of Technology7 papers (2019–2024)Priyanthi N.P. Gnanapragasam · California Institute of Technology7 papers (2014–2025)Louise Scharf · California Institute of Technology7 papers (2013–2017)Johannes F. Scheid · Broad Institute6 papers (2013–2022)Julio C. C. Lorenzi · Rockefeller University5 papers (2015–2022)Lilian Nogueira · Rockefeller University5 papers (2014–2019)Joshua A. Horwitz · Rockefeller University5 papers (2013–2017)Kathryn E. Huey‐Tubman · California Institute of Technology5 papers (2020–2024)Han Gao · California Institute of Technology5 papers (2013–2022)Anna Gazumyan · Rockefeller University5 papers (2014–2021)Jennifer R. Keeffe · California Institute of Technology5 papers (2021–2025)Jovana Golijanin · Brown University4 papers (2016–2022)Claudia A. Jette · Integrated BioTherapeutics (United States)4 papers (2020–2024)Marina Caskey · Rockefeller University4 papers (2015–2021)